14-3-3 alpha+beta (3C5) Monoclonal Antibody

Flow cytometric analysis of HeLa cells with 14-3-3 alpha+beta (3C5) Monoclonal Antibody (bsm-52710R) at 1:50 dilution (red) compared with an unlabeled control (cells without incubation with primary antibody; black).

$Lane 1: Hela Cells; Lane 2: 293T Cells; Lane 3: HepG2 Cells; Probed with 14-3-3 alpha+beta (3C5) Monoclonal Antibody (bsm-52710R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Lane 1: Hela Cells; Lane 2: 293T Cells; Lane 3: HepG2 Cells; Probed with 14-3-3 alpha+beta (3C5) Monoclonal Antibody (bsm-52710R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

$IF(ICC) staining with 14-3-3 alpha+beta (3C5) Monoclonal Antibody (bsm-52710R) at 1:300 in HeLa cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with 14-3-3 alpha+beta (3C5) Monoclonal Antibody (bsm-52710R) at 1:300 in HeLa cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with 14-3-3 alpha+beta (3C5) Monoclonal Antibody (bsm-52710R) at 1:300 in A431 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with 14-3-3 alpha+beta (3C5) Monoclonal Antibody (bsm-52710R) at 1:300 in A431 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with 14-3-3 alpha+beta (3C5) Monoclonal Antibody (bsm-52710R) at 1:300 in SHG-44 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with 14-3-3 alpha+beta (3C5) Monoclonal Antibody (bsm-52710R) at 1:300 in SHG-44 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$Paraformaldehyde-fixed and paraffin-embedded Human breast tissue incubated with 14-3-3 alpha+beta (3C5) Monoclonal Antibody (bsm-52710R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human breast tissue incubated with 14-3-3 alpha+beta (3C5) Monoclonal Antibody (bsm-52710R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human breast carcinoma tissue incubated with 14-3-3 alpha+beta (3C5) Monoclonal Antibody (bsm-52710R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human breast carcinoma tissue incubated with 14-3-3 alpha+beta (3C5) Monoclonal Antibody (bsm-52710R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Mouse brain tissue incubated with 14-3-3 alpha+beta (3C5) Monoclonal Antibody (bsm-52710R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Mouse brain tissue incubated with 14-3-3 alpha+beta (3C5) Monoclonal Antibody (bsm-52710R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Mouse skin tissue incubated with 14-3-3 alpha+beta (3C5) Monoclonal Antibody (bsm-52710R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Mouse skin tissue incubated with 14-3-3 alpha+beta (3C5) Monoclonal Antibody (bsm-52710R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

Applications

WB
FCM
IHC-P
IF(ICC)
IHC

Reactivity

Human
Mouse
Rat

Overview
Catalog #	bsm-52710R
Product Name	14-3-3 alpha+beta (3C5) Monoclonal Antibody
Applications	WB, FCM, IHC-P, IF(ICC), IHC
Reactivity	Human, Mouse, Rat
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Synthetic peptide corresponding to C terminal human 14-3-3 alpha + beta
Clonality	Monoclonal
Clone #	3C5
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide.
Storage Condition	Store at -20°C for 12 months.
Target
Gene ID	7529
Swiss Prot	P31946
Synonyms	14-3-3 protein beta/alpha, Protein 1054, Protein kinase C inhibitor protein 1, KCIP-1, YWHAB
Background	Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. Negative regulator of osteogenesis. Blocks the nuclear translocation of the phosphorylated form (by AKT1) of SRPK2 and antagonizes its stimulatory effect on cyclin D1 expression resulting in blockage of neuronal apoptosis elicited by SRPK2.
Application Dilution
WB	1:300-5000
FCM	1:20-100
IHC-P	1:200-400
IF(ICC)	1:50-200
IHC